# RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial

> **NCT04625153** · PHASE2 · TERMINATED · sponsor: **RemeGen Co., Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **BIOLOGICAL:** RC18 160mg
- **BIOLOGICAL:** RC18 240mg

## Key facts

- **NCT ID:** NCT04625153
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-13
- **Primary completion:** 2026-04-03
- **Final completion:** 2026-04-03
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Sponsor Strategic Priority Adjustment
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04625153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04625153, "RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04625153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*